Nexalin Technology (NXL)

• Market cap: $33.8M
• 1 day: -14.05%
• 5 days: -32.91%
• 1 month: -30.79%
• 3 months: 278.85%
• 6 months: 139.09%
• Year to date: 560.31%
• 1 year: 806.90%
• 5 years: 16.89%
• 10 years: 16.89%
• Sector: Healthcare
• Industry: Electromedical & Electrotherapeutic Apparatus

About: Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Employees: 6

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

15% more funds holding

Funds holding: 13 [Q2] → 15 (+2) [Q3]

0.38% less ownership

Funds ownership: 4.43% [Q2] → 4.05% (-0.38%) [Q3]

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

52% less capital invested

Capital invested by funds: $568K [Q2] → $271K (-$297K) [Q3]